Effects of the storage conditions on the stability of natural and synthetic cannabis in biological matrices for forensic toxicology analysis: An update from the literature

Beraprost
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	B01AC19 (WHO) ;
Pharmacokinetic data
Bioavailability	50–70%
Metabolism	Unknown
Elimination half-life	35–40 minutes
Identifiers
	IUPAC name 4-{(1R,2R,3aS,8bS)-2-Hydroxy-1-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan-5-yl}butanoic acid;
CAS Number	88430-50-6 88475-69-8;
PubChem CID	6917951;
IUPHAR/BPS	1967;
ChemSpider	5293169 ;
UNII	35E3NJJ4O6;
ChEBI	CHEBI:135633;
ChEMBL	ChEMBL1207745 ;
CompTox Dashboard (EPA)	DTXSID7049136 ;
Chemical and physical data
Formula	C24H30O5
Molar mass	398.499 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C3=CC=CC(=C3O2)CCCC(=O)O)O)O;
	InChI InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15?,17-,19+,20+,21-,23-/m0/s1 ; Key:CTPOHARTNNSRSR-APJZLKAGSA-N ;
	(what is this?) (verify)

Beraprost is a pharmaceutical drug used in several Asian countries, including Japan and South Korea, as a vasodilator and antiplatelet agent.^[1] It is classified as a prostacyclin analog.^[1]^[2]

It has been studied for the treatment of pulmonary hypertension and for use in avoiding reperfusion injury.

Clinical pharmacology

As an analog of prostacyclin PGI₂, beraprost affects vasodilation, which in turn lowers blood pressure. Beraprost also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.

Dosage and administration

Beraprost is administered orally as a pill available in strength of 20 mcg. Dose ranges from 60 to 180 mcg in divided doses after meals.

References

^ ^a ^b "Beraprost". drugs.com.
^ Melian EB, Goa KL (2002). "Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension". Drugs. 62 (1): 107–33. doi:10.2165/00003495-200262010-00005. PMID 11790158.

[drugs-1] "Beraprost". drugs.com.

[2] Melian EB, Goa KL (2002). "Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension". Drugs. 62 (1): 107–33. doi:10.2165/00003495-200262010-00005. PMID 11790158.

[1]

[2]

Medications used in the management of pulmonary arterial hypertension (B01, C02)
Prostacyclin analogues	Beraprost Epoprostenol Iloprost Selexipag Treprostinil
Endothelin receptor antagonists	Ambrisentan Bosentan Macitentan Sitaxentan
PDE5 inhibitors	Sildenafil Tadalafil
sGC stimulators	Riociguat Vericiguat
Adjunctive therapy	Calcium channel blockers Diuretics Digoxin Oxygen therapy Warfarin

Clinical data

AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	B01AC19 (WHO)
Pharmacokinetic data
Bioavailability	50–70%
Metabolism	Unknown
Elimination half-life	35–40 minutes
Identifiers
IUPAC name 4-{(1R,2R,3aS,8bS)-2-Hydroxy-1-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan-5-yl}butanoic acid
CAS Number	88430-50-6^Y 88475-69-8
PubChem CID	6917951
IUPHAR/BPS	1967
ChemSpider	5293169^Y
UNII	35E3NJJ4O6
ChEBI	CHEBI:135633
ChEMBL	ChEMBL1207745^N
CompTox Dashboard (EPA)	DTXSID7049136
Chemical and physical data
Formula	C₂₄H₃₀O₅
Molar mass	398.499 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C3=CC=CC(=C3O2)CCCC(=O)O)O)O
InChI InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15?,17-,19+,20+,21-,23-/m0/s1^Y Key:CTPOHARTNNSRSR-APJZLKAGSA-N^Y
^NY (what is this?) (verify)